Results 171 to 180 of about 21,002 (228)

Comments on "Early health economic analysis of virtual reality therapy for pain management after surgery". [PDF]

Int J Surg
Pezeshkian A.
europepmc   +1 more source

Translation, cross-cultural adaptation and psychometric validation study of health instruments in Bangla: protocol for a systematic review of adherence to international standards. [PDF]

BMJ Open
Noor IN, Islam N, Alam S, Rahman ZS, Al Rakib MMN, Samad Deepa S, Parag DDD, Rahman MM.   +7 more
europepmc   +1 more source

Using Proportional and Absolute Shortfall in Reimbursement Decision-Making in the Netherlands: Implications for Oncology Drugs for Older Patients. [PDF]

Pharmacoeconomics
Reckers-Droog V, Redeker S, Busschbach J, Vijgen S, Link A, Timmers L.   +5 more
europepmc   +1 more source

Flexibility in the Modelling of Comparative Effectiveness in the Absence of Head-to-Head Comparisons in the NICE Single Technology Appraisal of Fenfluramine for Treating Seizures Associated with Lennox-Gastaut Syndrome: An External Assessment Group Perspective. [PDF]

Pharmacoeconomics
Fernández Coves A, Scholte M, Wolff R, Perry M, Sugden B, Chen J, Armstrong N, Joore M, Witlox W.   +8 more
europepmc   +1 more source

A Cost-Effectiveness Model of Semaglutide 2.4 mg, Resmetirom 80 mg, and Resmetirom 100 mg Versus Standard of Care for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis in the United States. [PDF]

Pharmacoeconomics
McGovern AJ, Cinfio F, Luo R.
europepmc   +1 more source

National Prescribing Trends of Direct-Acting Antivirals for Hepatitis C.

JAMA
Kishore S, Hayden M, Johnson M, Kesselheim AS, Rome BN.   +4 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Interventional Pharmacoeconomics

The Cancer Journal, 2020
Abstract The increasing cost of health care is a major challenge around the world, but particularly in the United States. One reason for increased costs is the rapidly rising cost of oncology drugs. Potential solutions to this problem involve broad changes to health policy. However, an alternative solution is the development of lower-cost off-
Daniel A, Goldstein, Garth W, Strohbehn, Anthony V, Serritella, David A, Hyman, Allen S, Lichter, Mark J, Ratain   +5 more
openaire   +2 more sources

Pharmacoeconomics and Aging

Drugs & Aging, 2009
The aging of the general population in industrialized countries has brought to public attention the increasing incidence of age-related clinical conditions, because the long-term impact of diseases on functional status and on costs are greater in older people than in any other age group.
Bustacchini, S., Corsonello, A., Onder, G., Guffanti, E. E., Marchegiani, F., Abbatecola, A. M., Lattanzio, F.   +6 more
openaire   +3 more sources